Systemic Sclerosis

Study 1

Criteria to qualify for study: Drug used in study:
  • Patients unwilling or unable to discontinue DMARDs for treatment of SSc at time of randomization will be excluded.
  • Patients with a history or presence of a 2nd autoimmune disease requiring immunosuppressive thereapy will be excluded

FHCRC 2533 - CBCI-224

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis

Study 2

Criteria to qualify for study: Drug used in study:
  • Patients must have diffuse cutaneous scleroderma with a skin score of ≥16.
  • Systemic sclerosis must be ≤ 7 yearsfrom the onset of first non-Raynaud's symtoms.
  • Patient must have presence of interstitial lung disease or left heart failure or histoyr of renal disease that is not active at the time of screening

FHCRC 2067 - CBCI-237

Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis